Loading clinical trials...
Loading clinical trials...
An Open, Multicenter, Randomized Controlled Clinical Study of Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer
Conditions
Interventions
Chidamide combined with exemestane (+/- goserelin)
Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)
Start Date
February 25, 2022
Primary Completion Date
July 31, 2022
Completion Date
January 31, 2025
Last Updated
February 23, 2022
NCT07191730
NCT06312176
NCT06797635
NCT07003841
NCT07396766
NCT06443645
Lead Sponsor
Shengjing Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions